We also suggest that IL‐25/IL‐33/TSLP axis may be the master regulator of abnormal epithelial–mesenchymal interaction and serve as a novel treatment target for chronic fibrotic lung disease, especially IPF (Figure 2). This evidence concerns the gene IL33 and idiopathic pulmonary fibrosis.